| Proposed Maximum Aggregate Value of Transaction | Fee Rate | Amount of Filing Fee | ||
| | (1), (2), (3) | $ | | $ |
| Fees Previously Paid | ||||
| Total Transaction Valuation | $ | |||
| Total Fees Due for Filing | $ | |||
| Total Fees Previously Paid | $ | |||
| Total Fee Offsets | $ | |||
| Net Fee Due | $ |
| (1) | Aggregate
number of securities to which transaction applies: As of the close of business
on July 20, 2026, the maximum number of securities of Crinetics
Pharmaceuticals, Inc. (the “Company”) to which this transaction applies is
estimated to be 123,242,416, which consists of (i) 106,061,721 shares of the
Company’s common stock, par value $0.001 per share (“Company Common Stock”),
which may be entitled to receive the merger consideration of $85.00 per share;
(ii) 14,266,735 shares of Company Common Stock subject to outstanding options
(“Company Stock Options”) to purchase Company Common Stock granted under the
Company’s 2018 Incentive Award Plan, 2015 Stock Incentive Plan and 2021
Employment Inducement Incentive Award Plan (collectively, as amended from time
to time, the “Company Stock Plans”), with a weighted average exercise price of
$31.38 per share; (iii) 2,813,919 shares of Company Common Stock subject to
outstanding restricted stock units of the Company granted under a Company Stock
Plan (“Company RSUs”); (iv) 12,041 shares of Company Common Stock subject to
RSUs that may be issued after July 20, 2026; and (v) 88,000 shares of Company
Common Stock subject to outstanding rights under the Company’s 2018 Employee
Stock Purchase Plan (“Company ESPP”) that may be issued after July 20, 2026. |
|
(2)
|
In
accordance with Rule 0-11 under the Exchange Act, the proposed maximum
aggregate value of the transaction estimated solely for the purposes of
calculating the filing fee was calculated based on the sum of: (i) the product
of 106,061,721 shares of Company Common Stock multiplied by the merger
consideration of $85.00 per share; (ii) the product of 14,266,735 shares of
Company Common Stock subject to outstanding Company Stock Options and $53.62
per share (which is the difference between the merger consideration of $85.00
per share and the weighted average exercise price of $31.38 per share); (iii)
2,813,919 shares of Company Common Stock subject to outstanding Company RSUs
multiplied by the merger consideration of $85.00 per share; (iv) 12,041 shares
of Company Common Stock subject to RSUs that may be issued after July 20, 2026
multiplied by the merger consideration of $85.00 per share; and (v) 88,000
shares of Company Common Stock subject to outstanding rights under the Company
ESPP multiplied by the merger consideration of $85.00 per share.
|
|
(3)
|
In
accordance with Section 14(g) of the Exchange Act, the filing fee was
determined by multiplying the sum calculated in the preceding sentence by
0.00013810.
|